.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Express Scripts
Boehringer Ingelheim
Harvard Business School
Cerilliant
Covington
Federal Trade Commission
Daiichi Sankyo
Fuji
Johnson and Johnson

Generated: September 20, 2017

DrugPatentWatch Database Preview

Eluxadoline - Generic Drug Details

« Back to Dashboard

What are the generic sources for eluxadoline and what is the scope of eluxadoline patent protection?

Eluxadoline
is the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eluxadoline has one hundred patent family members in thirty-five countries.

One supplier is listed for this compound.

Summary for Generic Name: eluxadoline

Tradenames:1
Patents:11
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list6
Clinical Trials: see list1
Patent Applications: see list15
Drug Prices:see low prices
DailyMed Link:eluxadoline at DailyMed

Pharmacology for Ingredient: eluxadoline

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Allergan Holdings
VIBERZI
eluxadoline
TABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: eluxadoline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,206Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,859,604Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,609,865Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: eluxadoline

Country Document Number Estimated Expiration
Eurasian Patent Organization201591768► Subscribe
World Intellectual Property Organization (WIPO)2014159245► Subscribe
LithuaniaPA2017005► Subscribe
Norway338203► Subscribe
Taiwan200539876► Subscribe
Taiwan201444590► Subscribe
New Zealand549842► Subscribe
BrazilPI0508820► Subscribe
South Africa200608587► Subscribe
Hong Kong1105967► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELUXADOLINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017005Lithuania► SubscribePRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017000010Germany► SubscribePRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017000009Germany► SubscribePRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES ENANTIOMER, DIASTEREOMER, RACEMATE ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
0865Netherlands► SubscribePRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Merck
UBS
McKinsey
Chinese Patent Office
Cerilliant
Covington
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot